UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000009910 |
|---|---|
| Receipt number | R000011612 |
| Scientific Title | A phaseII study of irinotecan with bevacizumab as third line treatment for patients with metastatic colorectal cancer after failure to irinotecan who have progressed on bevacizumab with oxaliplatin-based chemotherapy in second line. |
| Date of disclosure of the study information | 2013/01/30 |
| Last modified on | 2018/08/14 01:15:14 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A phaseII study of irinotecan with bevacizumab as third line treatment for patients with metastatic colorectal cancer after failure to irinotecan who have progressed on bevacizumab with oxaliplatin-based chemotherapy in second line.
Acronym
A phaseII study of irinotecan with bevacizumab as third line treatment for patients with metastatic colorectal cancer after failure to irinotecan who have progressed on bevacizumab with oxaliplatin-based chemotherapy in second line.
Scientific Title
A phaseII study of irinotecan with bevacizumab as third line treatment for patients with metastatic colorectal cancer after failure to irinotecan who have progressed on bevacizumab with oxaliplatin-based chemotherapy in second line.
Scientific Title:Acronym
A phaseII study of irinotecan with bevacizumab as third line treatment for patients with metastatic colorectal cancer after failure to irinotecan who have progressed on bevacizumab with oxaliplatin-based chemotherapy in second line.
Region
| Japan |
Condition
Condition
colorectal cancer
Classification by specialty
| Gastroenterology | Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the efficacy and safety of the combination of Irinotecan + Bevacizumab as third-line chemotherapy in the patients with unresectable advanced recurrent coloreatal cancer previously treated with Bevacizumab + fluorinated pyrimidine + L-OHP after failure to irinotecan.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Phase II
Assessment
Primary outcomes
Progression Free Survival
Key secondary outcomes
Safety
Overall Survival
Total Survival
Overall Response Rate
Disease Control Rate
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Irinotecan + Bevacizumab
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1.Written informed consent.
2.Age :>=20 years
3.Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.
4.Histological confirmation of colorectal cancer.
5.Advanced or recurrent colorectal cancer that is not amenable to curative resection.
6.Measurable or evaluable disease.
7.Progression after first-line chemotherapy for metastatic disease, including bevacizumab or anti-EGFR monoclonal antibody with irinotecan.
8.Patients who had a clinical benefit (confirmed stable disease (SD) for at least 6 months or clinical response) in primary treatment with irinotecan.
9.Progression during or after second-line chemotherapy for metastatic disease, including bevacizumab with fluorinated pyrimidine + L-OHP.( In the case of side effects, the treatment by bevacizumab + fluorinated pyrimidine after stopping L-OHP is continuable.)
10.Less than 75mg/m2/week irinotecan in primary treatment was administered.(in the case of the FOLFIRI regimen the dosage of irinotecan was decreased by the start of the 3rd cycle)
11.Vital organ functions (listed below) are preserved within 2 weeks prior to entry.
I.Leukocyte >=3,000/mm3
II.Neurtophils >=1,500/mm3
III.Platelets >=100,000/mm3
IV.Hemoglobin >=9.0g/dl
V.AST and ALT <= 100IU/l
(200IU/l in case of liver metastasis)
VI.Total bilirubin <= 2.0ml/dl
VII.Serum creatinine <= 1.2mg/dl
Key exclusion criteria
(1) Need to drain malignant celomic fluid.
(2)Radiological evidence of CNS metastases or brain cancer.
(3) Multiple primary cancers within 5 years.
(4) Complication of cerebrovascular disease or symptoms within 1 year.
(5)Any surgical treatments including skin-open biopsy, trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week.
(6) The patient who is planning the surgical treatment during trial.
(7)Administering antithrombotic drug within 10 days.
(8)Need to administrate or having anti-platelets therapy (including Methotrexate aspirin and NSAIDS).
(9) Evidence of bleeding diathesis or coagulopathy.
(10)Active gastrointestinal ulcer
(11)Current or previous (within the last 1 year) history of GI perforation.
(12)Non healing fracture
(13)Renal failure to be treated,3+ or higher proteinuria within 2 weeks prior to entry.
(14)Uncontrolled Hypertension
(15)Clinically significant (i.e. active) cardiovascular disease or past or current history (within the last 1 year) of myocardial infarction.
(16)History of the serious hypersensitivity for irinotecan or bevacizumab.
(17)Uncontrolled diarrhea
(18)Evidence of interstinal lung disease, or pulmonary fibrosis.
(19)History of organ transplantation.
(20)Uncontrolled infection
(21)Pregnant or lactating women or women of childbearing potential.
(22) Men without the intention of preventing conception.
(23) Other conditions not suitable for this study.
Target sample size
25
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoshinori Sakai |
Organization
Tsuchiura kyodo general hospital
Division name
Department of Gastroenterology
Zip code
Address
11-7 Manabeshinmachi, Tsuchiura, Ibaraki, Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Toshiki Masuishi |
Organization
Tsuchiura kyodo general hospital
Division name
Department of Gastroenterology
Zip code
Address
11-7 Manabeshinmachi, Tsuchiura, Ibaraki, Japan
TEL
Homepage URL
Sponsor or person
Institute
Tsuchiura kyodo general hospital
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 01 | Month | 30 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2013 | Year | 01 | Month | 17 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 02 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 01 | Month | 30 | Day |
Last modified on
| 2018 | Year | 08 | Month | 14 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011612
